Last quarter (Q4 2023), Affimed's total revenue was €―, a decrease of -100.00% from the same quarter last year. In Q4, Affimed's net income was €―. See Affimed’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	€ 22.19M	€ 8.28M	€ 41.35M	€ 40.37M	€ 28.36M	€ 21.39M
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	€ 8.28M	€ 41.35M	€ 40.37M	-	-
Operating Expense	€ 63.30M	€ 119.63M	€ 130.89M	€ 105.71M	€ 63.21M	€ 54.02M
Operating Income	€ -41.11M	€ -111.36M	€ -89.54M	€ -65.34M	€ -34.85M	€ -32.63M
Net Non Operating Interest Income Expense	€ -690.00K	€ 238.00K	€ 2.12M	€ 6.51M	€ 46.00K	€ 190.00K
Other Income Expense	€ 5.90M	€ -4.70M	€ 4.63M	€ 7.69M	€ -6.56M	€ 76.00K
Pretax Income	€ -35.90M	€ -105.94M	€ -86.00M	€ -65.21M	€ -41.37M	€ -32.36M
Tax Provision	-	€ 3.00K	€ 2.00K	€ 2.00K	€ 1.00K	€ 4.00K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	€ -35.90M	€ -105.94M	€ -92.05M	€ -65.22M	€ -41.37M	€ -32.37M
Basic EPS	€ -0.13	€ -7.09	€ -0.60	€ -0.48	€ -0.50	€ -0.50
Diluted EPS	€ -0.13	€ -7.09	€ -0.60	€ -0.48	€ -0.50	€ -0.50
Basic Average Shares	€ 147.33M	€ 14.94M	€ 153.42M	€ 135.87M	€ 83.47M	€ 64.24M
Diluted Average Shares	€ 147.33M	€ 14.94M	€ 153.42M	€ 135.87M	€ 83.47M	€ 64.24M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	€ 63.30M	€ 119.63M	€ 130.89M	€ 105.71M	€ 63.21M	€ 54.02M
Net Income From Continuing And Discontinued Operation	€ -35.90M	€ -105.94M	€ -92.05M	€ -65.22M	€ -41.37M	€ -32.37M
Normalized Income	€ -41.56M	-	-	-	€ -36.57M	€ -32.42M
Interest Expense	€ 789.00K	-	-	-	€ 95.00K	€ 483.00K
EBIT	€ -35.11M	-	€ -86.00M	€ -65.21M	€ -41.27M	€ -31.88M
EBITDA	€ -34.40M	-	€ -83.10M	€ -63.88M	€ -40.16M	€ -30.97M

Currency in EUR

Affimed Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing